^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RSPO3 overexpression

    i
    Other names: RSPO3, R-Spondin 3, Thrombospondin Type-1 Domain-Containing Protein 2, Thrombospondin, Type I, Domain Containing 2, Protein With TSP Type-1 Repeat, Roof Plate-Specific Spondin-3, R-Spondin-3, PWTSR, THSD2, R-Spondin 3 Homolog (Xenopus Laevis), R-Spondin 3 Homolog
    Entrez ID:
    84870
    Related biomarkers:
    Fusion
    Associations

    News

    Trials
    2ms
    RSPO3 regulates the radioresistance of Non-Small cell lung cancer cells via NLRP3 Inflammasome-Mediated pyroptosis. (PubMed, Radiother Oncol)
    The findings demonstrated that RSPO3 plays a crucial role in regulating NSCLC radioresistance via NLRP3 mediated pyroptosis. Targeting the RSPO3-NLRP3 inflammasome axis may offer a potential therapeutic strategy to enhance the efficacy of radiotherapy for NSCLC patients.
    Journal
    |
    NLRP3 (NLR Family Pyrin Domain Containing 3) • RSPO3 (R-Spondin 3) • RSPO1 (R-Spondin 1)
    |
    RSPO3 overexpression
    |
    rosmantuzumab (OMP-131R10)
    1year
    Upregulation of RSPO3 via targeted promoter DNA demethylation inhibits the progression of cholangiocarcinoma. (PubMed, Clin Epigenetics)
    Our findings suggest that increased methylation and decreased expression of RSPO3 may indicate a poor prognosis in CCA. Restoring RSPO3 expression by targeting promoter DNA demethylation could offer insights for precise treatment of CCA.
    Journal • Epigenetic controller
    |
    DNMT3A (DNA methyltransferase 1) • RSPO3 (R-Spondin 3)
    |
    RSPO3 overexpression
    2years
    R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer. (PubMed, J Pathol)
    © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
    Journal
    |
    RSPO2 (R-Spondin 2) • RSPO3 (R-Spondin 3) • RSPO1 (R-Spondin 1)
    |
    RSPO3 overexpression
    over2years
    R-spondin 3 inhibits high glucose-induced endothelial activation through LGR4/Wnt/β-catenin pathway. (PubMed, J Cardiovasc Pharmacol)
    Moreover, the inhibitory effect of R-spondin 3 on the expressions of VCAM-1, ICAM-1 and MCP-1 in high glucose-treated HUVECs could be blocked by knockdown of leucine-rich G protein coupled receptor 4 (LGR4, R-spondin 3 receptor) or the specific inhibitor of Wnt/β-catenin pathway. Taken together, R-spondin 3 could suppress high glucose-induced endothelial activation through LGR4/Wnt/β-catenin pathway.
    Journal
    |
    CCL2 (Chemokine (C-C motif) ligand 2) • RSPO3 (R-Spondin 3) • VCAM1 (Vascular Cell Adhesion Molecule 1) • RSPO1 (R-Spondin 1)
    |
    RSPO3 overexpression